Patents Assigned to INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
  • Patent number: 11059773
    Abstract: The present invention discloses a type-B crystal form of fenolamine, a preparation method thereof, and a composition and use thereof, more particularly a type-B crystal form of the fenolamine compound (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenylethyl)acrylamide, a preparation method thereof, and a composition and use thereof. Specifically, the present invention discloses the presence of a solid of a type-B fenolamine crystal form in solid state; a method for preparing the solid of type-B crystal form; and use of the solid of the type-B fenolamine crystal form as a pharmaceutical active ingredient in the manufacture of a medicament for prevention and treatment of Parkinson's disease (PD), improvement of learning and memory disorder, and treatment of memory loss and Alzheimer's disease (AD).
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: July 13, 2021
    Assignees: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES, SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
    Inventors: Yang Lv, Shiying Yang, Gengtao Liu, Dan Zhang, Xiuqi Bao, Ping Xie
  • Publication number: 20210078939
    Abstract: The present invention discloses a type-B crystal form of fenolamine, a preparation method thereof, and a composition and use thereof, more particularly a type-B crystal form of the fenolamine compound (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenylethyl)acrylamide, a preparation method thereof, and a composition and use thereof. Specifically, the present invention discloses the presence of a solid of a type-B fenolamine crystal form in solid state; a method for preparing the solid of type-B crystal form; and use of the solid of the type-B fenolamine crystal form as a pharmaceutical active ingredient in the manufacture of a medicament for prevention and treatment of Parkinson's disease (PD), improvement of learning and memory disorder, and treatment of memory loss and Alzheimer's disease (AD).
    Type: Application
    Filed: September 7, 2018
    Publication date: March 18, 2021
    Applicants: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES, SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
    Inventors: Yang LV, Shiying YANG, Gengtao LIU, Dan ZHANG, Xiuqi BAO, Ping XIE
  • Publication number: 20200157042
    Abstract: The present invention discloses a type-G crystal form of fenolamine, a preparation method thereof, and a composition and use thereof. In particular, disclosed is a type-G crystal form of the fenolamine compound (chemical name: trans-2-(2,5-dimethoxyphenyl)-3-(4-hydroxy-3-methoxyphenyl)-N-(4-hydroxyphenylethyl)acrylamide, a preparation method thereof, and a composition and use thereof. Specifically, the present invention discloses the presence of a solid of a type-G fenolamine crystal form in solid state; a method for preparing the solid of type-G crystal form; and use of the solid of the type-G fenolamine crystal form as a pharmaceutical active ingredient in the manufacture of a medicament for prevention and treatment of Parkinson's disease (PD), improvement of learning and memory disorder, and treatment of memory loss and Alzheimer's disease (AD).
    Type: Application
    Filed: September 7, 2018
    Publication date: May 21, 2020
    Applicants: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES, SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
    Inventors: Yang LV, Shiying YANG, Gengtao LIU, Dan ZHANG, Xiuqi BAO, Ping XIE
  • Patent number: 9066960
    Abstract: The present invention relates to an effective fraction of alkaloids and the effective fraction is prepared from mulberry twig and its active ingredients are a composition of alkaloids. Determined by HPLC, the percentage of the total alkaloids are 50% or more by weight in the effective fraction and the percentage of the compound 1-deoxynojirimycin is 30% or more by weight in the total alkaloids. The effective fraction of the invention is prepared as the following steps: the mulberry twig is extracted by solvents, and the extract is precipitated by alcohol precipitation or flocculation to remove the impurities, and then concentrated, purified by resin chromatography. The present invention also relates to a pharmaceutical composition containing the said effective fraction of alkaloids and to the use of the effective fraction of alkaloids according to claim 1-4 in preparing hypoglycemic agents.
    Type: Grant
    Filed: August 22, 2007
    Date of Patent: June 30, 2015
    Assignee: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Yuling Liu, Zhufang Shen, Zhen Chen, Renyun Wang, Xuejun Xia, Yueteng Chen, Quan Liu, Sujuan Sun, Mingzhi Xie
  • Patent number: 8729280
    Abstract: This invention discloses that the five crystal forms of XLF-III-43 can be used as crude drugs. The invention also relates to the preparation methods of the five crystal forms of XLF-III-43 as crude drugs, to the applications of the sterling of the five crystal forms of XLF-III-43 and mixed crystals in different proportions as medicinally active components to develop various kinds of medicines and compound medicines. In addition, this invention also relates to applying the crystal samples of XLF-III-43 as crude drugs to treat kidney dysfunction, cardiocerebral vessel diseases, hypertension, type II diabetic mellitus, complications of hypertension and diabetic mellitus, tumor, precancerosis, edema, and achieves therapeutic effects by enhancing blood drug levels resulted from effects of crystal forms in the processes of treating all kinds of diseases.
    Type: Grant
    Filed: November 28, 2009
    Date of Patent: May 20, 2014
    Assignee: Institute of Mataria Medica, Chinese Academy of Medical Sciences
    Inventors: Yang Lv, Xiaoguang Chen, Ping Xie, Li Zhang, Cheng Wang
  • Patent number: 8524744
    Abstract: Disclosed Arylamine ketones of formula (I), their preparation methods, the pharmaceutical compositions containing them and their use in preventing and/or treating the diseases related to the plaque-activating factors, especially in anti-inflammation and immunization, more especially in the treatment of the acute or chronic inflammation, such as, osteoarthritis, oarthritis deformans, etc.
    Type: Grant
    Filed: August 5, 2005
    Date of Patent: September 3, 2013
    Assignee: Institute of Mataria Medica, Chinese Academy of Medical Sciences
    Inventors: Liya Zhu, Wenjie Wang, Halhong Huang, Ziyun Lin, Liyuan Mou, Zhengui Nie, Yu He, Xueyu Ouyang, Shanying Peng, Dongfong Zhang, Jun Wei
  • Publication number: 20130150335
    Abstract: A paclitaxel/steroid complex comprising paclitaxel and steroid is disclosed. The molar ratio of paclitaxel to steroid is 1:0.2˜4, preferably 1:0.25˜2. A process for the preparation thereof and the use thereof in the manufacture of submicron emulsion, dry emulsion, self-microemulsifying system are also disclosed.
    Type: Application
    Filed: October 28, 2010
    Publication date: June 13, 2013
    Applicant: Institute of Mataria Medica, Chinese Academy of Medical Sciences
    Inventors: Yuling Liu, Xuejun Xia, Ruifang Guo, Pengxiao Zhang, Cuiping Zhou, Renyun Wang, Dujia Jin
  • Patent number: 8435962
    Abstract: The invention discloses triacetyl-3-hydroxyphenyladenosine represented by formula (I), the preparation, the pharmaceutical composition and the use thereof. Specially, the invention discloses a new compound of 2?,3?,5?-tri-O-acetyl-N6-(3-hydroxyphenyl)adenosine. Using hypoxanthine nucleoside as starting material, the compound is prepared by acetylating with acetic anhydride, chlorinating with thionyl chloride, and being substituted with 3-hydroxy aniline. The invention also discloses the pharmaceutical composition comprising triacetyl-3-hydroxyphenyladenosine. The dosage forms of the said pharmaceutical composition include tablet, capsule, pill, injection, sustained release preparation, controlled release preparation or particulate delivery system. The medicament for treatment or precaution of hyperlipemia prepared by the compound of the invention has the advantages of significant hypolipidemic activity, less toxicity and adverse effect as well as slow metabolism in vivo.
    Type: Grant
    Filed: March 10, 2009
    Date of Patent: May 7, 2013
    Assignee: Institute of Mataria Medica, Chinese Academy of Medical Sciences
    Inventors: Haibo Zhu, Song Wu, Linghua Hao, Kai Qu, Ping Zhu, Xing Wang, Wei Li
  • Publication number: 20120308616
    Abstract: A submicron emulsion of paclitaxel, the preparation method and the use thereof are disclosed. Said paclitaxel submicron emulsion comprises paclitaxel/steroid complex, oil for injection, water for injection, emulsifier, assistant emulsifier and isotonic agent, wherein the mole ratio of paclitaxel to steroid in the complex is 1:0.2˜4; preferably 1:0.25˜2. Said submicron emulsion is useful for the treatment for malignant tumor. The average particle diameter of the submicron emulsion is less than 400 nm and the pH Value is 3.5-6.
    Type: Application
    Filed: October 28, 2010
    Publication date: December 6, 2012
    Applicant: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Yuling Liu, Xuejun Xia, Ruifang Guo, Pengxiao Zhang, Rui Han, Zhaodi Fu, Cuiping Zhou, Renyun Wang, Dujia Jin
  • Publication number: 20120190703
    Abstract: The present invention relates to the salts of (+)-13a-(S)-deoxytylophorinine represented by the general formula (I), the preparation method thereof, the pharmaceutical compositions containing them, and their use as medicaments for prevention and/or treatment of cancer and/or inflammation disease.
    Type: Application
    Filed: July 9, 2010
    Publication date: July 26, 2012
    Applicant: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Shishan Yu, Xiaoguang Chen, Haining Lv, Yan Li, Song Xu, Shuanggang Ma, Zhenjia Liu, Yi Zhang, Jinping Hu
  • Publication number: 20120053143
    Abstract: The invention discloses triacetyl-3-hydroxyphenyladenosine represented by formula (I), the preparation, the pharmaceutical composition and the use thereof. Specially, the invention discloses a new compound of 2?,3?,5?-tri-O-acetyl-N6-(3-hydroxyphenyl)adenosine. Using hypoxanthine nucleoside as starting material, the compound is prepared by acetylating with acetic anhydride, chlorinating with thionyl chloride, and being substituted with 3-hydroxy aniline. The invention also discloses the pharmaceutical composition comprising triacetyl-3-hydroxyphenyladenosine. The dosage forms of the said pharmaceutical composition include tablet, capsule, pill, injection, sustained release preparation, controlled release preparation or particulate delivery system. The medicament for treatment or precaution of hyperlipemia prepared by the compound of the invention has the advantages of significant hypolipidemic activity, less toxicity and adverse effect as well as slow metabolism in vivo.
    Type: Application
    Filed: March 10, 2009
    Publication date: March 1, 2012
    Applicant: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Haibo Zhu, Song Wu, Linghua Hao, Kai Qu, Ping Zhu, Xing Wang, Wei Li
  • Publication number: 20110319401
    Abstract: This invention discloses that the five crystal forms of XLF-III-43 can be used as crude drugs. The invention also relates to the preparation methods of the five crystal forms of XLF-III-43 as crude drugs, to the applications of the sterling of the five crystal forms of XLF-III-43 and mixed crystals in different proportions as medicinally active components to develop various kinds of medicines and compound medicines. In addition, this invention also relates to applying the crystal samples of XLF-III-43 as crude drugs to treat kidney dysfunction, cardiocerebral vessel diseases, hypertension, type II diabetic mellitus, complications of hypertension and diabetic mellitus, tumor, precancerosis, edema, and achieves therapeutic effects by enhancing blood drug levels resulted from effects of crystal forms in the processes of treating all kinds of diseases.
    Type: Application
    Filed: November 28, 2009
    Publication date: December 29, 2011
    Applicant: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Yang Lv, Xiaoguang Chen, Ping Xie, Li Zhang, Cheng Wang
  • Publication number: 20110039921
    Abstract: The present invention discloses cephalomannine derivatives of general formula (I), a process for preparation of such cephalomannine derivatives, a composition containing such compounds, and use of said compounds in the manufacture of a medicament for the treatment of tumors, especially multidrug resistant tumors.
    Type: Application
    Filed: November 15, 2007
    Publication date: February 17, 2011
    Applicant: INSTITUTE OF MATARIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES
    Inventors: Weishuo Fang, Xiaoguang Chen, Chungang Yang, Xuan Li, Hongbo Wang, Hongyan Liu, Rui Han, Limin Zhao